GILD · News · 20260805N

Trodelvy and Livdelzi Demand

GILEAD SCIENCES, INC. · 2026-08-05 · Importance 50 · Surprise 58

Gilead identified Trodelvy in oncology and Livdelzi in liver disease as additional contributors to base-business growth. These products complemented the HIV portfolio in driving 10% year-over-year base-business sales growth. Trodelvy’s performance indicates continued commercial demand in oncology, although the company also discontinued a Phase III Trodelvy-Keytruda study. Livdelzi represented an expanding liver-disease product opportunity alongside the company’s established infectious-disease portfolio.

Key facts

• Trodelvy growth was highlighted as a contributor to the Q2 revenue beat and outlook raise. source